title: [Anti-tumor effects induced by fusion of interleukin-18 gene transfected NCI-H460 lung cancer cell line with dendritic cells].
abstract: OBJECTIVE
  To explore the anti-tumor effects induced by fusion of interleukin (IL)-18 gene transfected lung cancer cell line NCI-H460 cells with dendritic cells (DC).
  
  
  METHODS
  (1) DC were induced from human monocytes and fused with IL-18 transfected NCI-H460 cells. Fusion was selected using MACS microbeads. (2) Four groups (group GT, group PT, group NT and group BC) were set up. T cells activated by IL-18 gene transfected fusion or pcDNA3. 1 + vector transfected fusion and non-transfected fusion were taken as effetor cells. No effector cells was in group BC. Lactic dehydrogenase ( LDH) method was used to evaluate the antitumor effect in vitro. (3) Tumor-bearing nude mice were inoculated with effector cells mentioned above. The tumor size and weight in the 4 groups were compared.
  
  
  RESULTS
  The killing rate in vitro of 3 groups were 53. 14% ,30. 10% and 31.49% , respectively. The tumor size and weight in the 3 groups were lower than group BC, among which group GT was the lowest.
  
  
  CONCLUSIONS
  Fusion of IL-18 gene transfected NCI-H460 lung cancer cells with dendritic cells can effectively induce anti-tumor immunity in the host.
authors.affiliation: Department of Oncology, The Second Hospital of Shandong University, Jinan 250033, China.
authors.forename: Zai-yun
authors.initials: ZY
authors.lastname: Zhang
authors.forename: Jin-min
authors.initials: JM
authors.lastname: Wu
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D002459:Cell Fusion; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology*; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D020382:Interleukin-18 / Q000235:genetics / Q000378:metabolism*; D008175:Lung Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008213:Lymphocyte Activation; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014162:Transfection; D023041:Xenograft Model Antitumor Assays / Q000379:methods*
chemical_list: D019496:Cancer Vaccines; D020382:Interleukin-18